Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack

Recent clinical trials with chimeric antigen receptor (CAR) redirected T cells targeting CD19 revealed particular efficacy in the treatment of leukemia/lymphoma, however, were accompanied by a lasting depletion of healthy B cells. We here explored CD30 as an alternative target, which is validated in...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Ther
Glavni autori: Hombach, Andreas A, Görgens, André, Chmielewski, Markus, Murke, Florian, Kimpel, Janine, Giebel, Bernd, Abken, Hinrich
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5023391/
https://ncbi.nlm.nih.gov/pubmed/27112062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2016.82
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items